In three small clinical trials, IL-6 blockers [42, 43], and IL-1ra-treatment [44], were effective in decreasing disease activity and in alleviating fatigue when used for treating IL-6-mediated Castleman’s disease. This evidence concerns the gene IL6 and Castleman disease.